News from Bayer
March 20, 2023
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China
March 01, 2023
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
March 01, 2023
Not intended for U.S. and UK Media
Bayer submits aflibercept 8 mg for marketing authorization in Japan
Explore All Stories
Select Topic
Please enter a term to search
We found 1 results